Journal of Pharmacy Practice

Lietman PS : Aminoglycosides: Rationale for therapeutic drug monitoring, in Tanaka K , Pippenger CE , Mimaki T, et al (eds): Advances in Therapeutic Drug Monitoring. Proceedings of the First International Congress of Therapeutic Drug Monitoring. Tokyo, Enterprise , 1990, pp 297-302

McCormack JP , Jewesson PJ : A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 14:320-339, 1992

Zaske DE : Aminoglycosides, in Evans WE , Schentag JC , Jusko W (eds): Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring , 2nd ed. Spokane, WA, Applied Therapeutics, 1986

Moore RD , Smith CR , Lietman PS : Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 77:657-662, 1984

Moore RD , Lietman PS , Smith CR : Clinical response to aminoglycoside therapy: Importance of the ratio of the peak concentration to minimum inhibitory concentration. J Infect Dis 155:93-98, 1987

Gilbert D. : Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35:399-405, 1991

Craig WA , Vogelman B. : The postantibiotic effect. Ann Intern Med 106:900-902, 1987

Daikos GL , Jackson GG , Lolans VT , Livermore DL : Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 162:414-420, 1990

Nicolau DP , Belliveau PP , Freeman CD, et al : Once-daily aminoglycosides: Experience with 500 patients in a hospital-wide program (abstract 85. Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy . New Orleans, LA, October, 1993

Rotschaefer JC , Rybak MJ : Single daily dosing of aminoglycosides: A commentary. Ann Pharmacother 28:797-801, 1994

Cantu TG , Yamanaka-Yuen NA , Lietman PS : Serum vancomycin concentrations: A reappraisal of their clinical value. Clin Infect Dis 18:533-543, 1994

Stratton CW , Weeks LS : Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn Microbiol Infect Dis 13:245-252, 1990

Flandrois JP , Fardel G. , Carret G. : Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus . Antimicrob Agents Chemother 32:454-457, 1988

Ackerman BH , Vannier AM , Eudy EB : Analysis of vancomycin time-kill studies with Staphlococcus species by using a curve stripping program to describe the relationship between concentrations and pharmacodynamic response . Antimicrob Agents Chemother 36:1766-1769, 1992

Vogelman BS , Craig WA : Postantibiotic effects. J Antimicrob Chemother 15:37-41, 1985 (suppl A)

Matzke GR , McGlory RW , Halstenson CE , Keane WF : Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437, 1984

Cimino MA , Rotstein C. , Slaughter RL , Emrich LJ : Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy . Am J Med 83:1091-1097, 1987

Sheiner LB , Tozer TN : Clinical pharmacokinetics: The use of plasma concentrations of drugs , in Melmon KL , Morelli HF (eds): Clinical Pharmacology: Basic Principles in Therapeutics. New York, NY, Macmillan, 1978, pp 71-109

Winter ME , Tozer TN : Phenytoin, in Evans WE , Schentag JJ , Jusko WJ (eds): Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring , 2nd ed. Spokane, WA, Applied Therapeutics, 1986, pp 494-539